Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
Study Achieves Primary and Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight with Once-Daily VK2735 Dosing as Compared to Placebo Up to 12.2% (26.6 lbs) Mean Weight Loss Observed After 13 Weeks of VK2735 Treatment Compared with 1.3% (2.9 lbs) for...
Related Questions
What are the potential risks (regulatory, safety, reimbursement) that could offset the upside from the reported weight‑loss efficacy?
How will the positive Phase 2 results affect VKN's short‑term price movement and trading volume?
What are the timelines and probability of moving to Phase 3, and how does that compare to other obesity‑treatment pipelines?